Loading…
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine
•A rapid and sensitive LC–MS/MS method developed to quantify lurbinectedin in human plasma and urine.•The assay has successfully been validated in the 0.1–100 and 1–1000 ng/mL ranges.•The assay was successfully applied for quantification of lurbinectedin in plasma and urine in a mass balance study....
Saved in:
Published in: | Journal of pharmaceutical and biomedical analysis 2018-09, Vol.158, p.160-165 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •A rapid and sensitive LC–MS/MS method developed to quantify lurbinectedin in human plasma and urine.•The assay has successfully been validated in the 0.1–100 and 1–1000 ng/mL ranges.•The assay was successfully applied for quantification of lurbinectedin in plasma and urine in a mass balance study.
Lurbinectedin is a novel highly selective inhibitor of RNA polymerase II triggering caspase-dependent apoptosis of cancerous cells. This article describes the development and validation of a liquid chromatography-tandem mass spectrometry (LC–MS/MS) assay to quantify lurbinectedin in human plasma and urine. Plasma samples were pre-treated with 1 M aqueous ammonia after which they were brought onto supported liquid extraction (SLE) columns. Lurbinectedin was eluted from the columns using tert-butyl methyl ether (TBME). Urine was first diluted in plasma and lurbinectedin was extracted from this matrix by liquid-liquid extraction using TBME. Samples were measured by LC–MS/MS in the positive electron ion spray mode. The method was linear over 0.1–100 ng/mL and 1–1000 ng/mL in plasma and urine, respectively, with accuracies and precisions within ±15% (20% for LLOQ) and below 15% (20% for LLOQ), respectively. The method was developed to support a mass balance study in which patients received a dose of 5 mg lurbinectedin. |
---|---|
ISSN: | 0731-7085 1873-264X |
DOI: | 10.1016/j.jpba.2018.05.053 |